Evogene Overview
Evogene is a computational biology company focused on revolutionizing product discovery and development in multiple life sciences-based industries, including human health and agriculture, through the use of its broadly applicable computational predictive biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of big data and artificial intelligence, has been designed to computationally discover and guide the development of life sciences products based on microbes, small molecules, and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd, medical cannabis through Canonic Ltd, agricultural biologicals through Lavie Bio Ltd, agriculture chemicals through AgPlenus Ltd, and agriculture solutions for castor oil production through Castera Ltd.
Cumulative Funding Raised Over Time ($)
$2.0MApr 2008
$20.0MAug 2008
$25.5MAug 2024
$34.0MJul 2023
$41.0MMar 2006
$51.0MSep 2020
Latest News
growth-positive
Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Evogene Ltd., a computational biology and chemistry company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The companys President and CEO, Ofer Haviv, will present on September 10, 2025, focusing on Evogenes strategic emphasis on ChemPass AI, a proprietary generative AI tech-engine. This technology is designed for the discovery and optimization of small molecules in the pharmaceutical and agriculture sectors. The presentation aims to highlight the potential of ChemPass AI in increasing success rates and reducing development costs. Evogenes innovation is driven by strategic partnerships and collaborations, alongside its internal product pipelines.
growth-positive
Evogene Declares The Sale Of Lavie Bio’s Activity To ICL Completed
ICL Group Ltd has acquired Lavie Bio Ltd, a subsidiary of Evogene Ltd, in a strategic move to enhance its position in the global ag-biologicals market. The acquisition includes Lavie Bios patented technology platform, microbial bank, and commercial products, along with the transfer of key personnel to ICL. This transaction is expected to boost ICLs innovation pipeline and promote sustainable agricultural solutions. The acquisition was first announced on April 21, 2025. Despite the positive outlook for ICL, the article suggests that certain AI stocks may offer better investment opportunities.
Acquisition
growth-negative
Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ...
Evogene Ltd reported an increase in total revenues for the first half of 2025, driven by strong seed sales from its subsidiary Casterra. The company reduced operating expenses significantly and completed the sale of Lavie Bios assets and the MicroBoost AI for Ag tech-engine to ICL, enhancing its financial position. Evogene raised $4.4 million through its ATM facility, providing a financial runway of approximately 18 months. However, the company is undergoing a strategic shift, including workforce reductions, which may impact employee morale and operational stability. Challenges include uncertainty in commercializing Casterras castor seed inventory and geopolitical risks in Israel. The company is focusing on maximizing the value of its ChemPass AI platform, strengthened by a collaboration with Google Cloud.
LayoffsInvestmentPartnersAcquisition
growth-positive
Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a...
Evogene Ltd. reported its financial results for the first half of 2025, highlighting a strategic shift towards AI-driven innovation with its ChemPass AI platform. The company completed the sale of Lavie Bios activities and the MicroBoost AI for Ag platform to ICL for $18.71 million, boosting its cash position. Evogene also raised $4.4 million through an at-the-market facility, reflecting strong market confidence. The company is focusing on enhancing ChemPass AI, expanding strategic collaborations in pharma, and integrating AgPlenus activities. Evogene executed a 30% workforce reduction to streamline operations and improve efficiency. The company is leveraging partnerships with Google Cloud and Tel Aviv University to advance its AI capabilities in pharmaceuticals and agriculture.
AcquisitionInvestmentLayoffsPartnersCustomers
growth-negative
Evogene: Q2 Earnings Snapshot
Evogene Ltd., an agricultural company based in Rehovot, Israel, reported a financial loss of $4.5 million for its second quarter. The companys loss translates to 62 cents per share, with a reported revenue of $884,000 for the period. This financial update suggests a challenging quarter for Evogene, impacting its growth negatively. The report was generated using data from Zacks Investment Research.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $135.7M |
| Last funding | $5.5M |
| Stage | Public |
| Rounds | 10 |
| Investors | 9 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | evogene.com |
| Careers | Careers page |
Locations
13 Derech Gad Feinstein, Rehovot, Israel
Rehovot, Israel
Photos & Videos
No files yet
Evogene Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Climate TechFood & Land UseSustainable FarmingAgriculture & Food TechnologiesAg TechGenetics & InputHealth Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Agriculture & FoodHealthcare & Life SciencesLife SciencesPharmaceuticalsIndustrial ManufacturingCore Technology
Artificial IntelligenceBiologicalsGenesTags (14)
cropsbiotechnologyplant-genomicsagtechbreedingbig-databiofuelclimate-techgenomicschemicalsartificial-intelligencegeneticsseedspharmaceuticalsEvogene Financials
$135.7M
Total funding
Undisclosed
Capital raised
$5.5M
Last funding
Public
Funding stage
10
Total rounds
9
Investors
Cumulative Funding Raised Over Time ($)
$2.0MApr 2008
$20.0MAug 2008
$25.5MAug 2024
$34.0MJul 2023
$41.0MMar 2006
$51.0MSep 2020
Private Equity Funding
PIPE
Aug 2024
$5.5M
Undisclosed Investor(s)
PIPE
Jul 2023
$8.5M
SilverArc Capital Management, Alliance Global Partners, LP and CVI Investments, Inc., Altium Capital Management
PIPE
Sep 2020
$10M
ARK Investment Management (Lead)
,
Alpha Capital Anstalt
PIPE
Aug 2008
$18M
Monsanto (Lead)
,
AAF Group
PIPE
Apr 2008
$2M
Undisclosed Investor(s)
Undisclosed Round
Mar 2006
$7M
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
May 2023
$1.3M
Horizon Europe (Lead)
GrantEvent
Jan 2018
$1.4M
Israel Innovation Authority
Public Offering / Exit
POEvent
Nov 2013
Undisclosed
POEvent
Jun 2007
Undisclosed
Evogene Lifecycle
Cumulative Funding Raised Over Time
$2.0MApr 2008
$20.0MAug 2008
$25.5MAug 2024
$34.0MJul 2023
$41.0MMar 2006
$51.0MSep 2020
All Events
PIPE
Aug 2024
$5.5M
Undisclosed Investor(s)
PIPE
Jul 2023
$8.5M
SilverArc Capital Management, Alliance Global Partners, LP and CVI Investments, Inc., Altium Capital Management
PIPE
Sep 2020
$10M
ARK Investment Management (Lead)
,
Alpha Capital Anstalt
PIPE
Aug 2008
$18M
Monsanto (Lead)
,
AAF Group
PIPE
Apr 2008
$2M
Undisclosed Investor(s)
Undisclosed Round
Mar 2006
$7M
Undisclosed Investor(s)
GrantEvent
May 2023
$1.3M
Horizon Europe (Lead)
GrantEvent
Jan 2018
$1.4M
Israel Innovation Authority
POEvent
Nov 2013
Undisclosed
POEvent
Jun 2007
Undisclosed
Evogene News
151 articles
growth-positive
Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Evogene Ltd., a computational biology and chemistry company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The companys President and CEO, Ofer Haviv, will present on September 10, 2025, focusing on Evogenes strategic emphasis on ChemPass AI, a proprietary generative AI tech-engine. This technology is designed for the discovery and optimization of small molecules in the pharmaceutical and agriculture sectors. The presentation aims to highlight the potential of ChemPass AI in increasing success rates and reducing development costs. Evogenes innovation is driven by strategic partnerships and collaborations, alongside its internal product pipelines.
growth-positive
Evogene Declares The Sale Of Lavie Bio’s Activity To ICL Completed
ICL Group Ltd has acquired Lavie Bio Ltd, a subsidiary of Evogene Ltd, in a strategic move to enhance its position in the global ag-biologicals market. The acquisition includes Lavie Bios patented technology platform, microbial bank, and commercial products, along with the transfer of key personnel to ICL. This transaction is expected to boost ICLs innovation pipeline and promote sustainable agricultural solutions. The acquisition was first announced on April 21, 2025. Despite the positive outlook for ICL, the article suggests that certain AI stocks may offer better investment opportunities.
Acquisition
growth-negative
Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ...
Evogene Ltd reported an increase in total revenues for the first half of 2025, driven by strong seed sales from its subsidiary Casterra. The company reduced operating expenses significantly and completed the sale of Lavie Bios assets and the MicroBoost AI for Ag tech-engine to ICL, enhancing its financial position. Evogene raised $4.4 million through its ATM facility, providing a financial runway of approximately 18 months. However, the company is undergoing a strategic shift, including workforce reductions, which may impact employee morale and operational stability. Challenges include uncertainty in commercializing Casterras castor seed inventory and geopolitical risks in Israel. The company is focusing on maximizing the value of its ChemPass AI platform, strengthened by a collaboration with Google Cloud.
LayoffsInvestmentPartnersAcquisition
growth-positive
Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a...
Evogene Ltd. reported its financial results for the first half of 2025, highlighting a strategic shift towards AI-driven innovation with its ChemPass AI platform. The company completed the sale of Lavie Bios activities and the MicroBoost AI for Ag platform to ICL for $18.71 million, boosting its cash position. Evogene also raised $4.4 million through an at-the-market facility, reflecting strong market confidence. The company is focusing on enhancing ChemPass AI, expanding strategic collaborations in pharma, and integrating AgPlenus activities. Evogene executed a 30% workforce reduction to streamline operations and improve efficiency. The company is leveraging partnerships with Google Cloud and Tel Aviv University to advance its AI capabilities in pharmaceuticals and agriculture.
AcquisitionInvestmentLayoffsPartnersCustomers
growth-negative
Evogene: Q2 Earnings Snapshot
Evogene Ltd., an agricultural company based in Rehovot, Israel, reported a financial loss of $4.5 million for its second quarter. The companys loss translates to 62 cents per share, with a reported revenue of $884,000 for the period. This financial update suggests a challenging quarter for Evogene, impacting its growth negatively. The report was generated using data from Zacks Investment Research.
growth-negative
Evogene Reports Second Quarter 2025 Financial Results
Evogene Ltd. reported its financial results for the first half of 2025, showing an increase in revenue to $3.2 million, primarily due to higher seed sales by Casterra. However, the company also reported a decrease in operating expenses to $7.7 million, attributed to reduced activity in its subsidiaries. Evogene is undergoing a strategic transformation, focusing on its ChemPass AI platform for discovering and optimizing small molecules. The company has sold Lavie Bios assets and the MicroBoost AI for Ag tech-engine to ICL, completed in July 2025. This sale is part of Evogenes repositioning strategy to enhance innovation and operational efficiency in pharmaceuticals and agriculture. The company is also implementing a cost reduction plan, with full effects expected in the second half of 2025.
Acquired-byLayoffs
growth-positive
/PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the...
Evogene Ltd., a computational biology and chemistry company, has announced a collaboration with Professor Ehud Gazits research group from Tel Aviv University. This partnership aims to accelerate the discovery and optimization of novel small molecules to treat diseases caused by the ordered self-assembly of small metabolites, such as Tyrosinemia and Gout. The collaboration will leverage Evogenes ChemPass AI platform and Professor Gazits expertise in molecular self-assembly to design therapeutics that inhibit pathological processes. This collaboration represents a significant milestone for Evogene in using AI-driven drug design to address complex medical challenges and improve patient outcomes.
growth-positive
Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
Evogene Ltd., a computational biology and chemistry company, has announced a scientific collaboration with Professor Ehud Gazits research group from Tel Aviv University. This partnership, facilitated by Ramot, aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for diseases caused by the ordered self-assembly of small metabolites. The collaboration will leverage Evogenes ChemPass AI for generative molecular design and Professor Gazits expertise in molecular self-assembly. The goal is to develop therapeutics that inhibit pathological self-assembly processes, potentially benefiting millions of patients with diseases like Tyrosinemia and Gout.
Partners
growth-positive
Evogene Schedules Second Quarter 2025 Financial Results Release
Evogene Ltd., a computational biology company, announced it will release its financial results for the first quarter of 2025 on August 19, 2025. The company will host a conference call to discuss these results. Evogene leverages big data and artificial intelligence to develop life-science-based products through its tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbes, small molecules, and genetic elements, respectively. The company collaborates with strategic partners and subsidiaries such as Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd. to advance its product development.
growth-positive
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and...
Evogene Ltd., a computational biology company, announced it will release its financial results for Q1 2025 on August 19, 2025. The company leverages big data and AI to revolutionize life-science product development. Evogene has developed three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different core components. The company collaborates with strategic partners and operates through subsidiaries such as Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., each focusing on different applications of their tech-engines. A conference call to discuss the financial results will be held on the same day.
growth-positive
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL
Evogene Ltd. has completed the divestiture of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd. This transaction includes the transfer of Lavie Bios proprietary technology platforms and personnel to ICL. Evogenes MicroBoost AI platform for agriculture has also been transferred to ICL. The divestiture aligns with Evogenes strategy to unlock the value of its subsidiaries and technology. Lavie Bios existing partnerships and agreements remain under its ownership, potentially benefiting its shareholders. The acquisition by ICL is expected to enhance its capabilities in the ag-biologicals market and contribute to sustainable agricultural solutions.
Acquired-by
growth-positive
Agricultural Biotechnology Market Outlook Report to 2030, with Profiles of Bayer, Corteva, Syngenta, BASF, FMC, Bioceres Crop Solutions, Evogene, Marrone Bio Innovations, Calyxt & Arcadia Biosciences
The agricultural biotechnology market is experiencing significant growth, driven by advancements in gene editing, precision breeding, and AI integration. The market expanded from USD 58.47 billion in 2024 to USD 65.60 billion in 2025 and is projected to reach USD 113.24 billion by 2030, with a CAGR of 11.64%. This growth is fueled by the demand for climate-resilient and sustainable solutions, as well as regional innovation and strategic alliances. The market encompasses various crop types, trait types, and application areas, with leading companies like Bayer, Corteva, and Syngenta playing key roles. The focus on food security and regulatory progress further supports this upward trajectory.
growth-positive
/PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing life-science product discovery and...
Evogene Ltd., a computational biology company, has announced the completion of its generative AI foundation model, version 1.0, for small molecule design. Developed in collaboration with Google Cloud, this model enhances Evogenes ChemPass AI by addressing the challenge of identifying novel small molecules that meet complex product criteria in the pharmaceutical and agriculture sectors. The model, built on a dataset of 38 billion molecular structures, offers approximately 90% precision in novel molecule designs. This advancement is expected to reduce late-stage failures in pharma and develop effective, sustainable ag-chemicals. Evogene is also working on version 2.0 of the model, focusing on multi-parameter optimization. The company continues to engage with partners in the pharmaceutical and agriculture industries.
PartnersProduct Stage
growth-positive
Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud
Evogene Ltd., a computational biology company, has announced the completion of its generative AI foundation model, version 1.0, for small molecule design. Developed in collaboration with Google Cloud, this model enhances Evogenes ChemPass AI by addressing the challenge of identifying novel small molecules that meet multiple complex product criteria, crucial for pharmaceutical and agriculture applications. The model supports the simultaneous consideration of complex requirements, facilitating the development of strong intellectual property portfolios. Built on a dataset of approximately 38 billion molecular structures, the model was trained using Google Clouds advanced AI infrastructure. This breakthrough is expected to significantly improve the precision and novelty of molecule designs, marking a substantial advancement over traditional methods.
growth-negative
Evogene Ltd (EVGN) Q1 2025 Earnings Call Highlights: Strategic Expense Reductions and Promising ...
Evogene Ltd reported a decrease in revenue to $2.4 million in Q1 2025 from $4.2 million in Q1 2024, primarily due to the absence of license fee payments. The company reduced its R&D expenses significantly and reported a net loss of $3 million, an improvement from the previous year. Evogene announced the acquisition of Lavie Bios activities by ICL for $15.25 million. The company is advancing its ChemPass AI for pharma and requires additional funding to advance Biomicas BMC128 to Phase II clinical trials. Evogene is facing challenges in educating farmers on its castor seed varieties, impacting sales growth. The company plans to further reduce expenses to extend its financial runway through 2026.
AcquisitionProduct StagePartnersCustomers
growth-negative
Evogene Reports First Quarter 2025 Financial Results
Evogene reported a decrease in total revenues for the first quarter of 2025 compared to the same period in 2024, primarily due to the absence of significant license fee payments that were present in the previous year. The company has implemented an expense reduction plan, which has led to decreased R&D and sales and marketing expenses. Evogene announced the acquisition of most of Lavie Bios activities by ICL for $15.25 million, along with the sale of MicroBoost AI for Ag for $3.5 million. This transaction is expected to generate value for Evogene through direct sales and dividends, as it remains a major shareholder in Lavie Bio. The companys cash balance at the end of Q1 2025 was $9.8 million, excluding expected proceeds from the asset sale.
AcquisitionCustomers
growth-negative
Evogene: Q1 Earnings Snapshot
Evogene Ltd., an agricultural company based in Rehovot, Israel, reported its first-quarter earnings, revealing a loss of $2.6 million, which translates to a loss of 38 cents per share. The companys revenue for the period was $2.4 million. This financial performance indicates a growth-negative impact on the company. The report was generated using data from Zacks Investment Research and highlights the companys current financial challenges.
growth-positive
Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4...
Evogene Ltd. reported its financial results for the first quarter of 2025, highlighting a decrease in revenues compared to the previous year due to reduced license fee payments. However, the company is focusing on strategic initiatives to drive growth, including the acquisition of Lavie Bios operations by ICL for $15.25 million, and the sale of MicroBoost AI for Ag for $3.5 million. Evogene is leveraging its AI tech-engines to enhance product development in life sciences, with significant progress in its ChemPass-AI platform for drug discovery. The company is also implementing an expense reduction plan and exploring strategic opportunities across its subsidiaries to unlock shareholder value.
AcquisitionProduct StageInvestmentPartnersCustomers
growth-positive
Evogene Schedules First Quarter 2025 Financial Results Release
Evogene Ltd., a computational biology company, announced it will release its financial results for the first quarter of 2025 on May 21, 2025. The company will host a conference call to discuss these results. Evogene leverages big data and artificial intelligence to develop life-science-based products, utilizing three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbes, small molecules, and genetic elements, respectively. Evogene collaborates with strategic partners and operates through four subsidiaries: Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., each focusing on different applications of their tech-engines.
growth-positive
Why Evogene Ltd. (EVGN) Soared on Monday
Evogene Ltd. (NASDAQ:EVGN) experienced a significant stock price increase, jumping 30.93% to $1.27, after announcing the sale of a controlling stake in Lavie Bio Ltd. to ICL, a global specialty minerals and chemicals company. This acquisition includes Evogenes MicroBoost AI for AG platform and is expected to be completed in the second quarter of the year. The deal will provide ICL access to Lavie Bios assets, including its core team, technology platform, and commercial products, enhancing its position in the ag-biologicals sector. Despite the broader market downturn, Evogene was among the top-performing micro- to small-cap stocks, reflecting positive investor sentiment towards the acquisition.
Acquisition
growth-positive
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Evogene Ltd. announced a definitive agreement for ICL to acquire the majority of activities of its subsidiary, Lavie Bio Ltd., including the MicroBoost AI for AG platform. The transaction is expected to close in the second quarter of 2025. Lavie Bio, a leader in the ag-biologicals industry, will transfer key assets such as its core team, technology platform, microbial bank, data assets, development programs, and commercial products to ICL. Existing agreements with Lavie Bios partners will remain with Lavie Bio. This acquisition follows strategic investment and collaboration between ICL and Lavie Bio, aiming to advance innovative bio-stimulant solutions for agriculture.
Acquired-byPartners
growth-positive
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product...
Evogene Ltd., a computational biology company, has entered into a definitive agreement with ICL to acquire the majority of its subsidiary, Lavie Bio Ltd. This acquisition includes Lavie Bios core team, BDD technology platform, microbial bank, data assets, and commercial products. Additionally, ICL will acquire Evogenes MicroBoost AI for AG platform. The transaction is expected to close in the second quarter of 2025. This strategic move follows more than two years of collaboration between ICL and Lavie Bio, focusing on developing bio-stimulant solutions for agriculture. The integration of Lavie Bios activities into ICL is anticipated to advance the global ag-biologicals field and drive innovation in agriculture.
Acquired-byPartners
growth-negative
אבוג'ן מוכרת לאיי.סי.אל פעילות פיתוח של מאיצי צמיחה ב-18 מיליון דולר
אבוגן, a company involved in crop enhancement and discovery of growth accelerators and biological pesticides using computational technologies, is experiencing financial distress. To alleviate cash flow issues, the company is selling its subsidiary, Lavie Bio, which will reduce its cash consumption by $8 million annually. This move is intended to delay the need for equity fundraising and shareholder dilution. Despite the companys valuation plummeting to $6.5 million, a 99.5% drop from its peak in 2013, the stock surged by 27% following the announcement. The sale is part of a strategy to stabilize the companys finances.
Acquisition
growth-positive
Evogene Ltd (EVGN) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
Evogene Ltd reported a significant increase in total revenues for 2024, reaching approximately $8.5 million, up from $5.6 million in 2023. The company addressed a bottleneck in seed production, with a notable delivery of 250 tons of Castor seeds in February 2025. Evogene established a collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule design, enhancing its drug discovery capabilities. The company implemented an expense reduction plan, resulting in a 30% reduction in headcount, which is expected to improve financials starting Q1 2025. Despite increased revenues and decreased R&D expenses, the company reported an operating loss of approximately $22.2 million for 2024. The change in the delivery schedule of Castera seeds led to lower-than-expected Q4 2024 revenues.
CustomersPartnersLayoffs
growth-negative
Evogene: Q4 Earnings Snapshot
Evogene Ltd., an agricultural company based in Rehovot, Israel, reported a profit of $427,000 for its fourth quarter, equating to 6 cents per share. Despite this quarterly profit, the company experienced a significant annual loss of $16.5 million, or $2.89 per share, with total revenue for the year amounting to $8.5 million. The financial results indicate a challenging year for Evogene, highlighting the disparity between quarterly and annual performance. The data for this report was sourced from Zacks Investment Research and processed by Automated Insights.
growth-positive
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
Evogene Ltd., a computational biology company, announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon. Mr. Nimrodi brings extensive experience in the life sciences sector and has been involved with Evogene since 2020. His leadership is expected to guide the company through its next phase of growth, leveraging advanced computational capabilities and AI to drive product innovation. Ms. Firon will continue to serve as a Board member. The company is focused on unlocking significant value for its shareholders through strategic initiatives.
Management Changes
growth-positive
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery...
Evogene Ltd., a computational biology company, announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon. Mr. Nimrodi brings extensive experience in life sciences and aims to guide Evogenes growth and innovation, particularly in leveraging AI for product development. The company operates through strategic partnerships and subsidiaries, focusing on developing life-science-based products using advanced computational capabilities. Evogenes tech-engines, including MicroBoost AI, ChemPass AI, and GeneRator AI, support its product development efforts. The company is poised for growth, with a focus on unlocking value for shareholders and advancing drug discovery processes.
Management Changes
growth-positive
Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million...
Evogene Ltd., a computational biology company, reported significant financial growth in 2024, with revenues increasing to $8.5 million from $5.6 million in 2023. This growth was driven by increased seed sales from its subsidiary Casterra and a collaboration with Bayer. The company reduced R&D expenses by ending Canonics activities and decreasing expenses in other subsidiaries. Evogene plans to focus on AI-powered drug discovery using its ChemPass AI tech-engine and aims to create exit events for some subsidiaries to support its activities. The company also announced a 30% headcount reduction to align with strategic goals. Evogenes cash position at the end of 2024 was $15.3 million.
CustomersPartnersInvestmentManagement ChangesLayoffs
growth-negative
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results
Evogene Ltd. reported its financial results for 2024, showing an increase in total revenues to $8.5 million, up from $5.6 million in 2023, primarily due to increased revenues from AgPlenus collaboration with Bayer and Casterras seed sales. However, the company faced challenges with delivery schedules, impacting Q4 2024 revenues. Evogene implemented an expense reduction plan, reducing R&D expenses and headcount by 30% to align with strategic goals. Despite these efforts, the company incurred one-time expenses related to fundraising and doubtful debt. The company plans to continue delivering seeds from its inventory throughout 2025.
CustomersPartnersLayoffs
growth-positive
Evogene Schedules Fourth Quarter 2024 Financial Results Release
Evogene Ltd., a computational biology company, announced it will release its financial results for Q4 2024 on March 6, 2025. The company will host a conference call to discuss these results. Evogene leverages big data and AI to develop life-science products, utilizing tech-engines like MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbes, small molecules, and genetic elements, respectively. Evogene collaborates with strategic partners and operates through subsidiaries such as Biomica, Lavie Bio, AgPlenus, and Casterra Ag, each specializing in different areas of life-science product development.
growth-positive
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and...
Evogene Ltd., a computational biology company, announced it will release its financial results for Q4 2024 on March 6, 2025. The company will host a conference call to discuss these results. Evogene leverages big data and AI to revolutionize life-science product development, using three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbes, small molecules, and genetic elements, respectively. Evogene collaborates with strategic partners and operates four subsidiaries: Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., each focusing on different applications of their technologies.
growth-positive
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
AgPlenus Ltd., a subsidiary of Evogene Ltd., has announced a breakthrough in developing a novel Mode of Action (MoA) against Zymoseptoria tritici, a fungal pathogen affecting wheat crops. Through virtual screening and experimental testing, AgPlenus identified promising compounds that inhibit fungal growth. The company utilized advanced tools like TargetSelector™ and PointHit™ to discover and test these compounds in laboratory and greenhouse trials. Encouraged by the results, AgPlenus plans to optimize these molecules further using the ActiveSearch™ tool. This development aligns with their mission to provide sustainable crop protection solutions, addressing the growing resistance of fungi to existing fungicides.
Product StagePartners
growth-negative
Evogene Ltd (EVGN) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities
Evogene Ltd reported a mixed financial performance for the first nine months of 2024. The company saw an increase in total revenue to approximately $6.9 million, up from $5.1 million in the same period of 2023. However, Q3 2024 revenue decreased to $1.8 million from $3.8 million in Q3 2023, primarily due to a significant license fee received in the previous year. Despite a slight reduction in operating and net losses compared to 2023, the company faced increased general and administrative expenses. Evogene successfully raised $5.5 million in August 2024 and announced a collaboration with Google Cloud to enhance its AI capabilities. Casterra, a subsidiary, faced operational challenges due to weather conditions in Kenya, while Lavie Bio expanded its product offerings. The financial outlook remains cautious with increased financial expenses and operational delays.
InvestmentPartners
growth-negative
Evogene: Q3 Earnings Snapshot
Evogene Ltd., an agricultural company based in Rehovot, Israel, reported a financial loss of $7.6 million for its third quarter. This translates to a loss of $1.31 per share. The companys revenue for the period was $1.8 million. The report was generated using data from Zacks Investment Research. The financial results indicate a challenging period for Evogene, reflecting a growth-negative impact on the company.
growth-negative
Evogene Reports Third Quarter 2024 Financial Results
Evogene Ltd., a computational biology company, reported its financial results for Q3 2024. The company experienced a decline in Q3 2024 revenues to $1.8 million from $3.8 million in Q3 2023, primarily due to a lack of a significant license fee payment received in the previous year. Despite this, Evogene anticipates revenue growth for the full year 2024, driven by Casterras seed sales. The company completed a $5.5 million fundraising in August 2024 and reduced its headcount by 16% to strengthen its cash position. Operating losses decreased slightly to $17.6 million for the first nine months of 2024 compared to $18.9 million in the same period of 2023. Evogene is exploring additional business opportunities to further bolster its financial standing.
InvestmentLayoffs
growth-positive
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has announced significant progress in the development of its bio-fungicide, LAV321, which targets downy mildew. Over three years of field trials in Europe, LAV321 demonstrated a 70% efficacy rate in protecting grapes from fungal diseases. This success has led to the decision to advance LAV321 to the final stage of product development towards commercialization. The global fungicide market is expected to grow significantly, and LAV321 is positioned as an environmentally friendly alternative to chemical solutions. The product is now entering the pre-commercial stage, with regulatory processes set to begin. Lavie Bios CEO expressed satisfaction with the results, highlighting the products integration into existing pest management practices.
CustomersPartners
growth-positive
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio Ltd., a subsidiary of Evogene Ltd., announced plans to expand the commercial availability of its bio-inoculant product, Yalos®, to soybean crops in the US by the spring of 2025. Following successful field trials in 2024, which demonstrated a yield increase of over 5% in soybeans, Lavie Bio aims to tap into the 86 million acres of soybean market potential in the US. The expansion is expected to more than double the market potential for Yalos®, which is already available for wheat and barley in North America. The company is also looking to expand Yalos® into Brazil and European markets in the future. The product is distributed in Canada by Winfield United and directly by Lavie Bio in the US.
CustomersExpand
growth-positive
Evogene Schedules Third Quarter 2024 Financial Results Release
Evogene Ltd., a computational biology company, announced it will release its third-quarter financial results for 2024 on November 21. The company will host a conference call later that day to discuss the results. Evogene leverages big data and AI to revolutionize life-science product development, utilizing its three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on developing products through strategic partnerships and collaborations. Evogene operates through four subsidiaries: Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., each focusing on different life-science applications. The announcement highlights Evogenes ongoing commitment to innovation and strategic growth in the life sciences sector.
growth-positive
Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
Evogene Ltd., a computational biology company, has announced a collaboration with Google Cloud to develop a foundation model for generative small molecule design. This partnership aims to enhance Evogenes ChemPass AI technology, which accelerates the discovery and development of novel life-science products. The collaboration will utilize Google Clouds AI and machine learning capabilities to create a model trained on a dataset of approximately 40 billion molecular structures. This initiative is expected to expedite drug discovery, reduce costs, and improve success rates in identifying promising drug candidates. Additionally, the model will support sustainable solutions in agriculture and other industries, addressing challenges like food security and resource optimization.
Partners
growth-positive
/PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery...
Evogene Ltd., a computational biology company, has announced a strategic collaboration with Google Cloud to develop a foundation model for generative small molecule design. This partnership aims to enhance Evogenes ChemPass AI technology, which focuses on discovering and developing novel small molecules for drug development and sustainable agriculture. By leveraging Google Clouds AI and machine learning capabilities, the collaboration seeks to expedite drug discovery processes, reduce costs, and improve success rates. The initiative also aims to address global challenges in agriculture, such as food security and crop protection, by developing innovative solutions. This collaboration underscores Evogenes commitment to innovation and positions it as a leader in computational predictive biology.
Partners
growth-positive
Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has achieved a significant milestone in its operational expansion in Africa by delivering its first shipment of over 100 tons of castor seeds to a customer in Africa. These seeds were cultivated and processed in Kenya, marking the completion of the entire cultivation and processing cycle within the country. This development is part of Casterras strategy to solidify its infrastructure in Africa, ensuring a stable supply of castor seeds for bio-based products and biofuel. The company is also working on developing new seed varieties with improved performance. The shipment supports local agricultural practices and provides a commercial advantage by reducing shipping costs.
Customers
growth-positive
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Evogene, a computational biology company, along with Watershed AC and Ben-Gurion University, received approval from the Israel Innovation Authority for a second-year grant to continue developing CRISPR technology for crustaceans. This collaboration aims to address limitations in gene editing for non-model organisms, focusing on enhancing traits like growth rate and disease resistance in species such as giant freshwater prawn, white leg shrimp, and red swamp crayfish. The global shrimp and crayfish markets are projected to grow significantly, highlighting the relevance of this technology. Evogenes GeneRator AI tech-engine played a crucial role in achieving the first-year goals, including producing edited giant freshwater prawns. The second-year target is to scale up the technology for industrial use and expand its application to other crustacean species.
Partners
growth-positive
/PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd....
Evogene, a computational biology company, along with Watershed AC and Ben-Gurion University, has received approval from the Israel Innovation Authority for a second-year grant to continue developing CRISPR technology for crustaceans. This collaboration aims to address limitations in gene editing for non-model organisms, focusing on traits like growth rate and disease resistance in species such as giant freshwater prawn, white leg shrimp, and red swamp crayfish. The first year of collaboration successfully achieved its goals, with Evogenes GeneRator AI tech-engine playing a crucial role. The second year will focus on scaling up the technology for industrial use. The growing global shrimp and crayfish markets highlight the relevance of this sustainable aquaculture technology.
Partners
growth-positive
Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals
Lavie Bio Ltd., a subsidiary of Evogene Ltd., announced it has received a grant from the Israel Innovation Authority to advance its MicroFermentor technology. This innovative technology aims to reduce application costs, extend shelf life, and prolong bacterial viability after field application. The grant will support the next phase of development towards commercialization. The MicroFermentor technology is expected to bring significant economic value by introducing new bacterial-based ag-biologicals to the market. Lavie Bio plans to implement this technology in its product pipeline and introduce it to collaboration partners. The global ag-biologicals market is growing rapidly, driven by increasing demand for sustainable agricultural practices.
Investment
growth-positive
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Evogene Ltd., a computational biology company, has announced definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares in a registered direct offering. The company also agreed to issue unregistered Series A and Series B ordinary warrants to purchase up to 1,692,308 ordinary shares. The combined purchase price of the offering is US$3.25. The gross proceeds from the offering are expected to be approximately US$5.5 million. The company intends to use the net proceeds of the offering for working capital and general corporate purposes.
Investment
growth-positive
Evogene Reports Second Quarter 2024 Financial Results
Evogene Ltd., a computational biology company, has announced its financial results for the second quarter of 2024. The company reported H1 2024 revenues of $5.1M, up from $1.3M in H1 2023, and Q2 2024 revenues of $914K, up from $654K in Q2 2023. The company also reported a H1 2024 loss of $9.8M, down from $14.8M in H1 2023, and a Q2 2024 loss of $6.0M, down from $7.8M in Q2 2023. The companys subsidiary, Casterra, received a $440K order for castor seeds from an existing customer for a new African country and completed a successful castor seed season in Brazil.
CustomersPartnersManagement Changes
Growth-Negative
Evogene: Q2 Earnings Snapshot
Evogene Ltd., an agricultural company based in Rehovot, Israel, reported a loss of $5.4 million in its second quarter. The company also reported a loss of $1.06 per share. Despite the losses, the company managed to post revenue of $914,000 in the same period.
Layoffs
Growth-Positive
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Evogene Ltd., a computational biology company, has regained compliance with Nasdaq Listing Rule 5550(a)(2) after maintaining a minimum bid price of $1.00 per share for 10 consecutive business days. The company uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries. These subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., each of which is focused on the discovery and development of products based on one of the following core components: microbes, small molecules, and genetic elements.
Public Trading
Growth-Positive
Evogene Schedules Second Quarter 2024 Financial Results Release
Evogene Ltd., a leading computational biology company, has announced that it will release its financial results for the second quarter of 2024 on August 22, 2024. The company will host a conference call later that day to discuss the results. Evogene uses its unique tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries, including Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd.
Management Changes
growth-positive
Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has successfully completed its current castor growing and harvesting season in Brazil. The seeds are planned to be shipped during the third quarter of this year. The castor harvesting season in Africa has also started as planned and is expected to supply the majority of seeds for 2024. The company expects to meet all its existing orders, amounting to ~$8.4M, with the castor seeds produced in 2024 in both Brazilian and African territories.
Customers
Neutral
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Evogene Ltd., a computational biology company, announced a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, to be implemented after market close on July 24, 2024. The Companys Ordinary Shares will begin trading on the Nasdaq Capital Market and the Tel Aviv Stock Exchange on a post-reverse split basis. The reverse share split was approved by the Companys shareholders at the Companys Annual Meeting of Shareholders held on June 13, 2024. The reverse split will adjust the number of issued and outstanding Ordinary Shares of the Company from approximately 50,790,000 Ordinary Shares to approximately 5,079,000 Ordinary Shares.
Public Trading
growth-positive
ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
ICL, a global specialty minerals company, and Lavie Bio Ltd., an ag-biologicals company and subsidiary of Evogene Ltd., have announced a significant milestone in their collaboration to develop bio-stimulant solutions for crops facing various abiotic stresses. Leveraging artificial intelligence, Lavie Bio has identified over a dozen novel microbial candidates believed to have commercial viability as bio-stimulants for crops grown under extreme weather conditions. The collaboration has aimed to deliver tangible benefits to farmers, including a 5% to 10% increase in yield. The success of this collaboration paves the way for field trials in the U.S. and Brazil in the second half of 2024.
Partners
growth-positive
Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
Lavie Bio, a subsidiary of Evogene Ltd., has announced the commercial expansion of its bio-inoculant product, Yalos™, to winter wheat following successful trials. This expansion effectively doubles the potential market for Yalos™. Winter wheat growers across the US will have access to Yalos™ for the upcoming 2024-2025 season. The company is also planning to expand Yalos™ into other key crops, such as soybean and canola, with ongoing field trials in North America and an expected commercial launch in 2025.
CustomersExpand
growth-positive
Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has received an additional purchase order valued at ~$440K from an existing customer. This order expands Casterras operations into a new African country and solidifies its unique offering in the bio-fuel market. The company expects that its previously announced seed production, now totaling 900 tons, will more than support this order, which is expected to be completed by Q4 2024. The remaining revenue from castor seed orders received during 2023 and in 2024 is expected to be approximately ~$8.4 million.
CustomersExpand
growth-positive
Evogene Reports First Quarter 2024 Financial Results
Evogene Ltd., a computational biology company, has announced its Q1 2024 financial results. The company reported a revenue of $4.2M, a significant increase from $0.6M in Q1 2023, and anticipates continued growth in 2024. The company also reported a net loss of $3.8M, down from $7.0M in Q1 2023. Evogene has ceased operations of its subsidiary Canonic, resulting in annualized savings of approximately $1.5 million. The company also announced new agreements and collaborations with various partners, including Corteva, Syngenta, and Bayer.
CustomersPartnersManagement ChangesExpand
growth-positive
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Biomica Ltd., a subsidiary of Evogene Ltd., has announced promising initial findings from an ongoing Phase 1 clinical trial of its microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, in patients with non-small cell lung cancer, melanoma, or renal cell carcinoma. All trial participants had experienced disease progression in prior immunotherapy treatment before joining the trial. The preliminary findings suggest potential benefits for patients facing advanced stages of these malignancies. The study remains ongoing and further data will be analyzed in the coming months.
InvestmentManagement Changes
growth-positive
Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has signed new agreements with both existing and new seed producers in Africa. These agreements are expected to support the production of approximately 500 tons of additional seeds, enabling the completion of standing orders by the end of 2024 and positioning Casterra to fulfill future orders. The new addition, together with previous agreements of approximately 400 tons of seeds announced in February this year, is expected to enable Casterra to fulfill the orders received in 2023 by the end of 2024.
PartnersExpand
Neutral
Evogene Schedules First Quarter 2024 Financial Results Release
Evogene Ltd., a computational biology company, has announced that it will release its financial results for the first quarter of 2024 on May 23, 2024. The company management will host a conference call to discuss the results. Evogene uses its unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - to develop products through strategic partnerships and collaborations. The company has four subsidiaries, including Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd.
growth-positive
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Biomica Ltd., a subsidiary of Evogene Ltd., announced that it will present preliminary data from its Phase 1 study of BMC128 at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study involves the use of BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy in refractory patients with non-small cell lung cancer, melanoma, or renal cell carcinoma. The results are expected to lay the groundwork for the next phase in Biomicas clinical development process.
Investment
growth-positive
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Biomica Ltd., a subsidiary of Evogene Ltd., will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting. The studies, led by Prof. Yehuda Ringel, tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427, which effectively reduced visceral pain, a major symptom of IBS. The results validate the findings of discovery research based on human data collected from patients with functional bowel disorders at the University of North Carolina.
Research
growth-positive
Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
Finally Foods, an AI-driven company specializing in molecular farming for the food sector, has secured pre-seed funding from The Kitchen FoodTech Hub (TKH) and the Israeli Innovation Authority (IIA). The company, which is committed to providing sustainable alternative sources to animal-based proteins, will be granted a license to utilize Evogenes AI technology. The global alternative proteins market was valued at around USD 17.6 billion in 2022, with an anticipated average CAGR of 12%, expected to reach USD 55 billion by 2032. Finally Foods aims to capture a share in this growing sector.
InvestmentPartners
growth-positive
Evogene Announces Filing of Annual Report on Form 20-F
Evogene Ltd., a leading computational biology company, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission. The report can be accessed on the companys investor relations website and on the SECs website. Evogene uses its unique tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries. These subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd.
Public Trading
Growth-Negative
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Evogene Ltd., a computational biology company, has been notified by the Nasdaq Stock Market that it is not in compliance with Nasdaq Rule 5550(a)(2) due to its share price being below $1.00 for the last 30 consecutive business days. The company has been given 180 days to regain compliance, failing which its shares could be delisted. Evogene has stated that it will consider all available options to regain compliance, including a potential reverse share split. The notification has no immediate effect on the companys Nasdaq listing or the trading of its shares.
Public Trading
growth-positive
Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
Lavie Bio Ltd., a subsidiary of Evogene Ltd., is extending its joint validation trials for its biofungicides with Bayer AG after successful first-year laboratory and greenhouse testing. The tests have demonstrated the efficacy of Lavie Bios biofungicides in addressing diseases that affect fruits and vegetables worldwide. The companies are progressing to a second year of validation trials in field experiments. The biofungicides provide a sustainable and responsible approach to disease management, demonstrating high efficacy in controlling oomycetes while minimizing environmental impact.
PartnersExpand
growth-positive
Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has been chosen by Ceres Global Ag Corp. as a supplier in its sustainability programs with grain producers. Ceres will integrate Lavie Bios bio-inoculant, YalosTM, into its regenerative agriculture initiatives across the USA and Canada. The collaboration aims to foster more efficient growing practices and offer tailored solutions to strategic customers. Lavie Bios mission aligns with Ceres commitment to regenerative agriculture, aiming to produce healthier food and foster a sustainable environment while increasing productivity and value.
Partners
growth-positive
Evogene Ltd. (NASDAQ:EVGN) Q4 2023 Earnings Call Transcript
Evogene Ltd. held its Q4 2023 earnings call on March 7, 2024. The company reported increased sales of subsidiary products, expansion beyond its current sectors, and continued revenue growth for the Evogene Group in 2024. The company also discussed potential transfer of Canonics operations to a third party, increased production of Casterra, and commercialization of AgPlenus and Lavie Bios products. The company ended 2023 with a solid cash balance of approximately $31.1 million and expects additional cash injections from collaborations and product sales.
CustomersPartnersManagement ChangesExpand
growth-positive
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
Evogene Ltd., a computational biology company, has announced its financial results for the fourth quarter and full-year period ending December 31, 2023. The company reported revenues of approximately $5.6 million in 2023, compared to approximately $1.7 million in 2022. The company has formed partnerships with world-leading companies including Lavie Bio with Corteva, ICL, and Syngenta; AgPlenus with Bayer and Corteva; Casterra with a global oil and gas company; Biomica with an investment by Shanghai Healthcare Capital; and Evogene with Verb Biotics and Colors. The company anticipates further partnerships, increased sales of subsidiary products, and expansion beyond its current sectors.
CustomersPartnersInvestmentExpand
Growth-Negative
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Evogene reported a quarterly loss of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.14. However, the companys revenues of $0.58 million for the quarter ended December 2023 missed the Zacks Consensus Estimate by 66.59%. Despite this, Evogene shares have increased by about 10.6% since the beginning of the year. The companys future performance will largely depend on managements commentary on the earnings call. The current consensus EPS estimate is -$0.07 on $10.18 million in revenues for the coming quarter and -$0.29 on $34.93 million in revenues for the current fiscal year.
InvestmentManagement Changes
growth-positive
AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides
AgPlenus Ltd., a subsidiary of Evogene Ltd., has announced a significant milestone in its collaboration with Corteva Agriscience for the development of novel herbicides. The milestone marks the successful identification of a new family of molecules exhibiting herbicidal effect through a novel Mode of Action (MoA), APCO-12, discovered by AgPlenus. The collaboration, which began in 2020, aims to develop a new MoA herbicide by merging Cortevas leadership in product discovery with AgPlenuss computational technology platform. The next phase will focus on optimizing the identified class of molecules towards a commercial-level product.
PartnersExpand
growth-positive
Casterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed Varieties
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has signed strategic agreements with existing and new seed producers in Brazil and Africa to increase its production capabilities of high-yielding, high-oil castor seeds. The agreements are expected to support additional production of approximately 400 tons of Casterras elite castor seeds in 2024 and establish long-term production infrastructure. The company is taking significant steps to strengthen its castor production capabilities for bio-based industries, such as biofuels and biopolymers.
PartnersExpand
growth-positive
Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has secured the second-half advance payment of $2.5 million from Corteva after meeting the licensing agreement requirements. This completes the $5 million advance payment outlined in the agreement signed in July 2023. The agreement grants Corteva exclusive rights to develop and commercialize Lavie Bios leading bio-fungicide product candidates. Lavie Bio is also eligible for additional future milestone payments and royalties from Cortevas expected future sales of these products.
PartnersInvestment
Neutral
Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024
Evogene Ltd., a computational biology company, has announced that it will release its financial results for the third quarter of 2023 on March 7th, 2024. The company will host a conference call to discuss the results. Evogene uses its unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - to develop products through strategic partnerships and collaborations. The company has five subsidiaries, each focusing on different areas of product development.
growth-positive
AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer
AgPlenus Ltd, a subsidiary of Evogene Ltd., has announced the appointment of Dr. Dan Jacob Gelvan as its new CEO, effective from February 19, 2024. Dr. Gelvan brings over three decades of experience in leading science and technology companies. Concurrently, Dr. Brian Ember, the current CEO of AgPlenus, will transition to the role of Chief Business Officer. Ofer Haviv, CEO of Evogene and chairman of AgPlenus, expressed his excitement about Dr. Gelvans appointment and thanked Dr. Ember for his contributions.
Management Changes
growth-positive
AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution
AgPlenus Ltd., a subsidiary of Evogene Ltd., has announced a licensing and collaboration agreement with Bayer AG. The partnership will leverage artificial intelligence (AI) to design and optimize crop protection chemistry, with the aim of developing a novel, sustainable broad-spectrum herbicide for farmers. The collaboration will use AgPlenuss AI-driven computational modeling technology to design and optimize molecules identified for their broad-spectrum herbicidal activity. Bayer will have the exclusive license for the development and commercialization of products developed within the collaboration.
PartnersInvestment
growth-positive
Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide
Syngenta Crop Protection and Lavie Bio Ltd., a subsidiary of Evogene Ltd., have announced a partnership for the discovery and development of new biological insecticidal solutions. The collaboration will utilize Lavie Bios technology platform to identify and optimize bio-insecticide candidates, and Syngentas global research, development, and commercialization capabilities. The partnership aims to address the global challenge of insects that pose a major threat to crop health, causing an estimated $70 billion a year in losses to the global economy.
Partners
growth-positive
Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation
Evogene Ltd. and Verb Biotics LLC. have entered into a collaboration agreement to develop new strains of probiotic bacteria that produce a highly sustainable quantity of microbial metabolites that improve human health and vitality. The collaboration will use Evogenes MicroBoost AI tech-engine and Verb Biotics extensive knowledge in the field of the microbiome. The probiotics market is expected to double and reach approximately $114 billion by 2031. The financial terms of the agreement were not disclosed.
Partners
growth-positive
Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit
Biomica Ltd., a clinical-stage biopharmaceutical company and subsidiary of Evogene Ltd., announced that its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug Development Summit Europe in Barcelona, Spain, from January 30 to February 1, 2024. The summit gathers leading drug developers and microbiome experts to discuss microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up. Dr. Haber will join two industry panel discussions and will be available for one-on-one meetings at the conference.
Management Changes
growth-positive
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
Biomica Ltd., a subsidiary of Evogene Ltd., has announced the completion of patient enrollment for its Phase I clinical trial. The trial is evaluating the safety and tolerability of Biomicas microbiome-based immuno-oncology drug candidate, BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy. The trial, which began on July 11, 2022, is being conducted on patients with non-small cell lung cancer, melanoma, or renal cell carcinoma who previously progressed on immunotherapy. Preliminary results are expected in H1 2024.
Customers
growth-positive
Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
Evogene (EVGN) is currently showing positive momentum in the stock market, with a Momentum Style Score of B and a Zacks Rank of #2 (Buy). Over the past week, shares are up 14.57% and the monthly price change is 43.94%. Over the past quarter, shares of Evogene have risen 101.96%, and are up 23.54% in the last year. In addition, the companys earnings estimate has moved higher, increasing from -$0.50 to -$0.47 in the past 60 days. These positive indicators suggest that Evogene is a promising pick for investors.
Investment
Growth-Positive
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024
Biomica Ltd., a clinical-stage biopharmaceutical company and a subsidiary of Evogene Ltd., is preparing to participate in the JP Morgan 42nd Annual Healthcare Week, which is scheduled to run from January 8 to 11, 2024, in San Francisco. Biomica will also be participating in the Biotech Showcase conference. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders.
Partners
growth-positive
Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has announced the appointment of Mr. Yoash Zohar as its new CEO, effective from January 1, 2024. Zohar will lead the companys expansion efforts, as it enters a new phase of mass production of castor seeds to meet the growing demand from the bio-diesel industry. The company plans to increase its castor seed production capacity through existing and new subcontractors in target-market locations. Casterra has also expanded its team, including experts in research and development, seed production, and customer support.
Management ChangesExpand
growth-positive
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Compugen, a member of the Medical sector, has been outperforming its peers this year, with a year-to-date return of 9.2%, compared to the sectors average loss of 6.3%. The companys full-year earnings estimate has also increased by 8.9% within the past quarter, indicating improving analyst sentiment and a positive earnings outlook. Compugen currently holds a Zacks Rank of #2 (Buy). Another stock in the Medical sector, Evogene, has also outperformed the sector with a year-to-date return of 4.3%.
Investment
growth-positive
Lavie Bio Announces a Distribution Agreement with WinField United Canada for its Bio-Inoculant Seed Treatment Yalos™
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has announced a distribution agreement with WinField United Canada for its bio-inoculant seed treatment Yalos™. The partnership is part of Lavie Bios 2024 sales growth strategy in Canada, focusing on key agricultural regions. The agreement will enhance Lavie Bios sales and distribution capability throughout Canada and the United States. The company also plans to engage with additional distribution partners to expand its sales reach throughout North America. Yalos™ has shown a yield advantage in wheat, durum, and barley, offering a 4:1 return on investment for farmers.
PartnersExpand
Growth-Positive
Bears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' Now
Evogene (EVGN) has been experiencing a downtrend, losing 5.5% over the past week. However, a hammer chart pattern formed in its last trading session, indicating a potential trend reversal. This pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. Additionally, Wall Street analysts have shown strong agreement in raising earnings estimates for this agricultural company, further enhancing its prospects of a trend reversal. The consensus EPS estimate for the current year has increased 6% over the last 30 days. EVGN currently has a Zacks Rank #2 (Buy), indicating it is in the top 20% of more than the 4,000 stocks that Zacks ranks.
Investment
growth-positive
Lavie Bio Announces Expansion of its Bio-Inoculant Product for Spring Wheat, Yalos™, to Durum and Barley
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has announced the expansion of its microbiome-based product, Yalos™, to include durum and barley, significantly broadening its potential market reach. This follows successful field trials conducted in the US in 2023 in durum and barley, which generated an average yield increase of over 7%. Yalos™ is a seed treatment that enhances production by improving soil nutrients, reducing environmental stress, and increasing yields. The products addressable market in the US and Canada is expected to increase by ~40% from 25 million acres to 35 million acres.
CustomersExpand
growth-positive
Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript
Evogene Ltd. held its Q3 2023 earnings call on November 15, 2023. The company reported a cash balance of $37.2 million across its subsidiaries and expects additional orders and collaborations to generate cash flow throughout 2024. The companys revenues for the quarter totaled $3.8 million, including $0.9 million from Casterras sales of castor seeds and $2.5 million generated by Lavie Bio as a licensing fee in its collaboration with Corteva. The company also highlighted the progress of its subsidiaries and their positive impact on Evogene.
CustomersPartnersInvestmentExpand
growth-positive
Evogene Reports Third Quarter 2023 Financial Results
Evogene Ltd., a computational biology company, has announced its financial results for Q3 2023. Despite significant challenges, the company and its subsidiaries continue to operate and innovate. The Evogene Group had a consolidated cash position of approximately $37.2 million at the end of Q3. The company has also invested in collaborations with industry leaders to leverage its AI tech-engines for product development. Evogenes subsidiaries, including Biomica, Lavie Bio, AgPlenus, Casterra, and Canonic, have made significant achievements in recent months. The company plans to invest more resources in Casterra due to the potential in the bio-diesel market.
CustomersPartnersInvestmentExpand
growth-positive
Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results
Lavie Bio Ltd., a subsidiary of Evogene Ltd., reported significant progress with its bio-fungicide LAV321, which showed positive results in 2023 field trials across Europe and the US, protecting against downy mildew and late blight diseases. The trials demonstrated an average efficacy rate of 60% against downy mildew in grapes and a 97% efficacy rate against leaf disease. The global fungicide market, valued at approximately $21 billion in 2022, is projected to experience robust growth with a compound annual growth rate (CAGR) of 6.4% in the coming years. Lavie Bios CEO, Amit Noam, announced that LAV321 will be tested in field trials by several multinational companies next year.
CustomersExpand
Neutral
Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023
Evogene Ltd., a computational biology company, has announced that it will release its financial results for the third quarter of 2023 on November 15, 2023. The company management will host a conference call to discuss the results. Evogene uses its unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - to develop products through strategic partnerships and collaborations, and its five subsidiaries. These subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd.
growth-positive
Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology
Colors Farm Ltd, Evogene Ltd, and Ben-Gurion University (BGU) have announced a collaboration to develop gene editing technology for crustaceans. The collaboration aims to enhance key traits such as growth rate, disease resistance, and environmental adaptation in crustaceans. The initiative has received a competitive grant from the Israel Innovation Authority. The global shrimp market is predicted to increase to US$ ~88 billion by 2028, and the global crayfish market is expected to grow at a CAGR of 31.5% over the forecast period of 2024-2032.
Partners
Evogene Provides Operational Update Amidst Current Security Situation in Israel
growth-positive
Casterra Delivers First Shipment of Castor Seeds to Africa
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has announced the shipment of its first batch of high-yield, high-oil castor seeds from Brazil and Zambia to Africa. The shipment, valued at US$1 million, is the first step in fulfilling US$11.3M purchase orders from a world-leading oil and gas company. The seeds were developed using Evogenes GeneRator AI tech-engine and have passed rigorous testing to meet industry standards. Casterra anticipates it will supply the remainder of these seed orders in the coming months.
CustomersPartners
growth-positive
Evogene Ltd. (NASDAQ:EVGN) Q2 2023 Earnings Call Transcript
Evogene Ltd. reported its Q2 2023 earnings, highlighting significant achievements and growth across its subsidiaries. The company announced the establishment of collaboration agreements with leading companies and new domains of activity. Evogenes subsidiary, Biomica, completed a $20 million financing round led by a $10 million investment from Shanghai Healthcare Capital. Another subsidiary, Lavie Bio, entered into a licensing agreement with Corteva, set to receive an initial payment of approximately $5 million. Casterra, another subsidiary, secured purchase orders totaling $11.3 million for the supply of its high-yield, high-oil proprietary castor seeds. Evogene also raised $8.5 million through a registered direct offering from institutional investors.
InvestmentPartners
growth-positive
Evogene (EVGN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Shares of Evogene have been struggling, but a hammer chart pattern suggests a potential trend reversal. Rising optimism among Wall Street analysts about the companys future earnings enhances the prospects of a trend reversal. The consensus EPS estimate for the current year has increased 15% over the last 30 days. Evogene currently has a Zacks Rank #2 (Buy), indicating a potential improvement in the companys prospects.
CustomersPartners
growth-positive
Evogene Reports Second Quarter 2023 Financial Results
Evogene Ltd., a computational biology company, has announced its financial results for Q2 2023. The company received purchase orders worth $11.3 million for Casterras elite castor seeds and executed a licensing agreement between Lavie Bio and Corteva, which includes an upfront payment of $5 million. Additionally, Biomica closed a financial round for $20 million, and Evogene secured total gross proceeds of $8.5 million from a fundraising round. The company also unveiled the latest enhancement to its ChemPass AI tech-engine, TargetSelector, and is increasing its efforts to establish direct collaborations with leading companies.
InvestmentPartnersCustomers
growth-negative
Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates
Evogene reported a quarterly loss of $0.17 per share, beating the consensus estimate. However, the companys revenues of $0.65 million missed expectations. The stock has underperformed the market this year. The companys earnings outlook is favorable, and it has a Zacks Rank #2 (Buy). The industry rank for Medical - Biomedical and Genetics is in the top 38%. A competitor in the same industry, LAVA Therapeutics N.V., is yet to report its results.
Customers
growth-positive
Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center
Biomica Ltd., a subsidiary of Evogene Ltd., has opened a second site at The Davidoff Cancer Center for its Phase I clinical trial of its immuno-oncology drug candidate, BMC128. The trial aims to assess the safety and tolerability of BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy for the treatment of refractory patients with non-small cell lung cancer, melanoma, or renal cell carcinoma. The opening of the new site represents a milestone in Biomicas commitment to advancing clinical research in immuno-oncology. The company is focused on developing therapies for antibiotic-resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal disorders.
CustomersPartners
Neutral
Evogene Schedules Second Quarter 2023 Financial Results Release & Conference Call for August 17, 2023
Evogene Ltd., a computational biology company, announced that it will release its financial results for the second quarter of 2023 on August 17, 2023. The company will also host a conference call to discuss the results. Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries. The company is leveraging big data and artificial intelligence to revolutionize the development of life-science-based products.
None
growth-positive
Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery
Evogene Ltd., a computational biology company, announces the addition of TargetSelector to its ChemPass AI tech-engine. TargetSelector is a new application that streamlines target-protein discovery for active molecule identification, assisting researchers in finding suitable target proteins for new products while reducing development time and resources. The companys subsidiary, AgPlenus, which focuses on developing ag chemicals, will be the first to benefit from this new improvement. The company believes this advancement positions them to forge strategic partnerships with industry leaders.
CustomersPartnersExpand
growth-positive
Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program
Biomica Ltd., a subsidiary of Evogene Ltd., has reported positive interim results from pre-clinical studies of its live bacterial consortia, BMC426 and BMC427, for the treatment of Irritable Bowel Syndrome (IBS). The studies were conducted in collaboration with the New York University Pain Research Center. The results revealed that animals treated with either BMC426 or BMC427 displayed significantly lower levels of visceral sensitivity compared to the placebo-treated group. Biomica plans to explore additional parameters related to pain reduction and the alleviation of other IBS symptoms in the coming year.
PartnersExpand
growth-positive
Lavie Bio Announces Licensing Agreement for Bio-Fungicides with Corteva Agriscience
Lavie Bio Ltd., a subsidiary of Evogene Ltd., has announced a licensing agreement with Corteva Inc., a leading ag innovation company. The agreement grants Corteva exclusive rights to further develop and commercialize Lavie Bios lead bio-fungicide product candidates targeting fruit rots and powdery mildew. The diseases have resulted in annual losses estimated at billions of dollars globally. The agreement comes after two years of independent field validation conducted by both companies.
Partners
growth-positive
Evogene Announces Pricing of US$8,500,000 Registered Direct Offering
Evogene Ltd., a computational biology company, has announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 8,500,000 ordinary shares in a registered direct offering at a purchase price of $1.00 per ordinary share. The gross proceeds from the offering are expected to be approximately $8,500,000. The company intends to use the net proceeds of this offering to further develop its product pipelines, enhance and expand its CPB platform and technological engines, and for working capital and general corporate purposes. The closing of the offering is expected to occur on or about July 19, 2023.
Investment
growth-positive
AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors
AgPlenus Ltd., a subsidiary of Evogene Ltd., has announced the appointment of Dr. Adrian Percy to its board of directors. Dr. Percy, who also serves on the board of Evogene Ltd., brings over 25 years of experience in the agricultural industry, including a stint as Head of Research & Development for Bayers Crop Science division. His appointment is expected to provide valuable guidance and strategic insights as AgPlenus continues to develop environmentally sustainable crop protection solutions.
Management Changes
growth-positive
Casterra Announces Additional $2.2 Million of Purchase Orders to Supply Castor Seeds for New African Territories
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has announced additional purchase orders worth $2.2 million to supply castor seeds for the cultivation of castor plants in new African territories. The castor seeds, developed with Evogenes GeneRator AI Tech Engine, will be used to produce oil for sustainable biofuel. Casterra specializes in developing high-yield castor varieties optimized for biofuel production. The demand for non-fossil oil for biodiesel is expected to increase, and castor oil is considered a standout candidate due to its carbon-neutral properties and ability to be cultivated on marginal lands. Casterras success in securing purchase orders confirms its value proposition in the sustainable biofuel industry. The company aims to meet the growing global demand for renewable energy.
Customers
growth-positive
TalkMarkets Announces Company Spotlight Featuring Evogene
TalkMarkets.com announces a company spotlight series featuring Evogene, an agri-tech and bio-tech company with a computational predictive biological platform technology. The article highlights Evogenes subsidiaries and their potential value, particularly Casterra, which recently received a $9 million initial purchase order. The article also mentions Evogenes technology platform and its conservative valuation, suggesting a potential upside of over 6X. The event described in the article occurred on June 22, 2023.
InvestmentCustomers
growth-positive
Casterra Signs a Framework Agreement with a World Leading Oil and Gas Company to Sell Its Castor Seeds for Sustainable Biofuel Production, with Initial Purchase Orders of $9.1 Million
Casterra Ag Ltd., a subsidiary of Evogene Ltd., has signed a framework agreement to sell seeds of its proprietary castor varieties to a leading oil and gas company for cultivation in specific African territories. The initial purchase orders are valued at $9.1 million and the seeds are expected to be delivered in 2023. Casterras high-yield, high-oil castor seed varieties are optimized for biofuel production. The biodiesel market is estimated to reach $190 billion by 2030, and the purchase orders can support approximately 1.5% of the current world demand for non-fossil oil for biodiesel. Casterra utilizes Evogenes GeneRator AI tech engine to develop high-performance seeds for biofuel production.
Customers
growth-positive
Lavie Bio Receives Canadian Regulatory Approval for Thrivus™, Expanding Global Reach
Lavie Bio, a subsidiary of Evogene Ltd., has received registration for Thrivus™ from The Canadian Food Inspection Agency, expanding the products sales territory. This approval is a significant milestone for Lavie Bios global expansion plan. Thrivus™ is a bio-inoculant seed treatment that increases wheat production and improves soil nutrients. The company plans to position Thrivus™ as a lead product in 2023 and broaden its application to other crops. Lavie Bio utilizes a proprietary computational predictive platform to develop bio-stimulant and bio-pesticide products. The company aims to support sustainable agriculture and reduce environmental impact while providing increased value to farmers.
CustomersExpand
growth-positive
Evogene Reports First Quarter 2023 Financial Results
Evogene Ltd., a computational biology company, has announced its Q1 2023 financial results. The company has made significant improvements in its AI tech-engines, MicroBoost AI and ChemPass AI, which support the discovery and development of microbe-based and small-molecule-based products respectively. Subsidiary Biomica closed a $20 million investment round led by Shanghai Healthcare Capital, valuing the company at $50 million post-money. Other subsidiaries, including Lavie Bio, AgPlenus, Canonic, and Casterra, have also made progress in their respective fields. Evogene maintains a solid financial position with approximately $28.8 million in consolidated cash, cash equivalents, and marketable securities as of March 31, 2023.
InvestmentExpand
growth-negative
Evogene (EVGN) Reports Q1 Loss, Misses Revenue Estimates
Evogene reported a quarterly loss of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.16. The companys revenues for the quarter missed the estimate by 26.32%. Evogene shares have lost about 5.7% since the beginning of the year. The companys earnings outlook is mixed, resulting in a Zacks Rank #3 (Hold) for the stock. The industry outlook for Medical - Biomedical and Genetics is positive. Lifecore Biomedical, another company in the same industry, is yet to report its results.
Customers
growth-positive
Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance
Evogene Ltd., a computational biology company, has been granted a €1.2 million grant from the EU Horizon Program to support the creation of oil-seed crops with high carbon-dioxide assimilation and enhanced drought tolerance. The project, named Crop4Clima, has a total budget of €2.5 million and is expected to be executed over 32 months. The goal is to develop crops that can assimilate 60% more carbon dioxide from the air while requiring 20% less water intake compared to standard agricultural practices. Partners in this project include the Max Planck Society, IN Society, and Agrobioinstitute.
InvestmentPartners
growth-neutral
Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023
Evogene Ltd. will release its financial results for the first quarter of 2023. The company will host a conference call to discuss the results. Evogene is a computational biology company leveraging big data and artificial intelligence to revolutionize life-science product development. It has three tech-engines focused on the discovery and development of products based on microbes, small molecules, and genetic elements. Evogene has five subsidiaries, including Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd. The companys website provides more information. Investor contacts are Kenny Green and Rachel Pomerantz Gerber.
Public Trading
Plantis Licenses Two of Canonic's Proprietary Cannabis Varieties to Expand its Offerings in the Israeli Market
growth-positive
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Evogene, an AI technology company, oversees five subsidiaries that use its platform to develop products for medical and agricultural industries. The companys stock price has been on a downtrend but its financial performance has continued to improve. Updates on its subsidiaries include Lavie Bio receiving a $10 million investment from ICL, Biomica developing three drug candidates, AgPlenus partnering with Corteva, Casterra signing agreements for castor seed supply, and Canonic releasing second-generation cannabis products. Evogenes revenues have been increasing, and it is currently undervalued. The company has a cash position of $31.860 million and expects future revenues from its subsidiaries and agreements. The article suggests that an investment opportunity may soon present itself.
InvestmentPartnersExpand
growth-positive
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
Biomica Ltd., a subsidiary of Evogene Ltd., has closed a financing round of $20 million. The round was led by a $10 million investment from Shanghai Healthcare Capital. The investment will enable Biomica to develop its pipeline of microbiome-based therapeutics, including advancing its immuno-oncology study and clinical trial for the treatment of inflammatory bowel disease. Evogene also invested $10 million in Biomica in the current financing round.
Investment
growth-positive
Evogene Announces Filing of Annual Report on Form 20-F
Evogene Ltd. has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission. The company is a computational biology company leveraging big data and artificial intelligence to revolutionize the development of life-science based products. Evogene uses its tech-engines to develop products through strategic partnerships and collaborations. The companys subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd. The Annual Report can be accessed on the companys investor relations website and the SECs website.
Public Trading
growth-positive
Lavie Bio Announces Appointment of Amit Noam as its Incoming Chief Executive Officer
Lavie Bio, a subsidiary of Evogene Ltd., has appointed Amit Noam as its new CEO. Noam has extensive experience in the agriculture and healthcare sectors and will lead Lavie Bio in its mission to improve food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products. Lavie Bio has impressive achievements and is supported by leading partners and investors, including Corteva and ICL Group. Noams appointment is expected to drive long-term growth and value-creation for the company. Lavie Bio aims to scale up manufacturing and increase sales for its bio-stimulant, advance its pipeline of products, and extend collaborations with global partners. The appointment marks a key juncture in Lavie Bios development.
Management Changes
growth-positive
Evogene Offers Stock Investors An Excellent Risk/Reward Ratio
Evogenes main CPB computational engine has the potential to be an extraordinary value creation engine. The company has five subsidiaries and one division, three of which already have products on the market. The company has no debt and has enough cash to last into next year with multiple additional sources of funding likely materializing at the subsidiary level well before that. The market cap ($27M) is a fraction of the potential with many of its subsidiaries likely exceeding that on an individual basis. The company has a proprietary CPB (Computational Predictive Biology) platform in order to greatly improve the chances of successful product discovery and speed up product development in life science industries through the use of big data and AI.
InvestmentPartners
growth-positive
Biomica VP R&D to Present at the Pharmabiotics 2023 Conference on March 21, 2023
Biomica Ltd., a subsidiary of Evogene Ltd., announced that its VP R&D will be presenting at the Pharmabiotics 2023 Conference. The presentation will focus on Biomicas BMC128, a rationally designed LBP consortiums journey to the clinic. BMC128 is currently being tested in a Phase 1 study to evaluate its safety and tolerability in combination with anti-PD-1 therapy. Biomica is a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, while Evogene is a computational biology company.
Partners
Evogene Ltd. (NASDAQ:EVGN) Q4 2022 Earnings Call Transcript
growth-positive
Evogene Reports Fourth Quarter and Full Year 2022 Financial Results
Evogene Ltd., a computational biology company, has announced its financial results for Q4 and the full year ending December 31, 2022. The company has made significant progress in advancing its AI technology and has seen success with its subsidiaries. Lavie Bio, a subsidiary focused on ag-biological products, received a $10 million SAFE investment and strategic collaboration with ICL. Biomica, another subsidiary, received a $10 million seed investment from Shanghai Healthcare Capital. Evogenes consolidated cash position stands at approximately $35 million as of December 31, 2022.
InvestmentPartnersCustomers
Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates
growth-positive
Lavie Bio to Host a Round Table Discussion and is a Sponsor at World Agri-Tech Conference in San Francisco
Lavie Bio, a subsidiary of Evogene Ltd., will be sponsoring and participating at the World Agri-Tech Conference in San Francisco. The companys EVP Commercial & US General Manager will be hosting a roundtable discussion on sustainability during the conference. Lavie Bio is one of the sponsors of the summit, which brings together growers, agribusiness leaders, technology pioneers, and investors. The company aims to improve food quality, sustainability, and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes Evogenes proprietary MicroBoost AI tech-engine for the discovery and development of bio-stimulant and bio-pesticide products.
Partners
growth-positive
AgPlenus to Attend World Agri-Tech Conference in San Francisco
Ag Plenus Ltd., a subsidiary of Evogene Ltd., announced that representatives from its management will be attending and participating at the World Agri-Tech Conference. The conference serves as a meeting place for the global agtech ecosystem, bringing together growers, agribusiness leaders, technology pioneers, and investors. Ag Plenus is a platform company designing effective and sustainable crop protection products, and it leverages computational biology and chemistry to achieve this. The company has ongoing collaborations with industry leaders such as Corteva. The attendance of Ag Plenus at the conference demonstrates its commitment to innovation and partnership in the agricultural technology sector.
Partners
growth-positive
Evogene to Attend the Annual ROTH Investor Conference in California on March 13, 2023
Evogene Ltd. announced its attendance at the 35th Annual ROTH Conference, where they will meet with investors. The conference will include one-on-one meetings, industry panels, presentations, and fireside chats. Evogenes Executive VP, Business Development, Eyal Ronen, will be participating in one-on-one meetings with analysts and investors. The company aims to revolutionize product development in life-science based industries by utilizing cutting-edge technologies and artificial intelligence. Evogene has established three tech-engines focused on microbes, small molecules, and genetic elements. They use these tech-engines to develop products through subsidiaries and strategic partnerships. The companys subsidiaries are currently developing various products, including human microbiome-based therapeutics, ag-biologicals, ag-chemicals, medical cannabis products, and castor varieties for the biofuel industry.
Investment
growth-positive
Biomica CSO to Present at the ECCO 2023 Annual Meeting in Copenhagen between March 1-4, 2023
Biomica, a subsidiary of Evogene Ltd., will be presenting at the 2023 ECCO Annual Meeting to share recent data from its IBD R&D pipeline. The presentation will focus on the anti-inflammatory effect and mechanism of action of BMC333, a live bacterial consortium for treating IBD. Biomica is a clinical-stage biopharmaceutical company developing microbiome-based therapeutics for antibiotic-resistant bacteria, immuno-oncology, and GI disorders. The company aims to identify disease-related microbiome entities and develop novel therapeutics based on these understandings. The presentation will take place on March 3, 2023, and Professor Yehuda Ringel, Biomicas Chief Scientific Officer, will be available for one-on-one meetings throughout the conference.
Partners
growth-positive
Lavie Bio Reports Successful Results for its Bio-Fungicides Programs
Lavie Bio, a subsidiary of Evogene Ltd., has announced progress in its bio-fungicides programs based on successful results from field trials conducted in 2022. The companys bio-fungicides LAV311 and LAV321 showed positive results in protecting crops against bunch rot, powdery mildew, and blight diseases. The demand for eco-friendly and sustainable solutions in crop protection is growing due to increasing disease resistance and public interest. Lavie Bios products are designed to be integrated into existing Integrated Pest Management practices. LAV311 is an optimized live microbial strain that provides improved protection against bunch rot diseases, while LAV321 targets oomycetes class diseases. The positive results support Lavie Bios plan to commercialize LAV311 in 2024. The company also plans to expand the potential addressable markets for LAV311 and LAV321 in the coming year.
CustomersInvestment
growth-neutral
Evogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022
Evogene Ltd. will release its financial results for the third quarter of 2022 on November 17, 2022. The company will host a conference call to discuss the results. Evogene is a computational biology company aiming to revolutionize the development of life-science based products through its technological engines and subsidiaries. The companys main subsidiaries develop products in the fields of human microbiome-based therapeutics, medical cannabis products, ag-chemicals, and ag-biologicals.
growth-positive
Evogene to Present at the LD Micro Main Event XV Investor Conference in Los Angeles
Evogene Ltd. announced that its President and CEO will attend and present at LD Micro Main Event, an investor conference. The presentation will focus on Evogenes disruptive technologies, AI engines for biologic product discovery and development, and its ecosystem of product-focused subsidiaries and partnerships. The conference will showcase over 200 small- and micro-cap companies.
InvestmentPartners
growth-negative
חברת הגנטיקה החקלאית שממציאה את עצמה מחדש
Israeli agrotech company Evogene has faced a series of challenges since signing a major partnership agreement with Monsanto 15 years ago. The company used big data and artificial intelligence to understand which genetic modifications to make in plants to give them properties such as drought resistance and improved yield. However, regulatory processes for new seeds were extended, opposition to genetic engineering arose, and Monsanto was acquired by Bayer in 2016. As a result, the products of the collaboration never reached the market. Evogene has since sought new revenue streams, applying its technological capabilities in other areas such as biological pest control, precise chemical pest control, cannabis, and the human microbiome.
PartnersInvestmentManagement Changes
growth-positive
Evogene Reports Third Quarter 2021 Financial Results
Evogene Ltd., a computational biology company, has released its financial results for Q3 2021 and the first nine months of the year. The companys CEO, Ofer Haviv, expressed satisfaction with the progress made and the milestones achieved by the company and its subsidiaries. Evogene is considering turning one or more of its subsidiaries into public companies to unlock their value. The companys cash position as of September 30, 2021, was $61.6 million. The company also announced management changes and recent achievements, including the appointment of a new CEO for AgPlenus, and the stepping down of Lavie Bios CEO.
Management ChangesInvestment
growth-positive
Evogene Announces Participation in the Second Research Period of the CRISPR-IL Consortium
Evogene has been informed by the Israeli Innovation Authority (IIA) that it will fund a second 18-month period of the CRISPR-IL consortium. The consortium aims to develop an end-to-end artificial intelligence system called Go-Genome for genome-editing in multiple species. The approval for the second period comes with an additional budget of approximately ILS 45 million ($14.4 million). Evogenes VP New Directions, Dr. Eyal Emanuel, serves as the Chairman of the consortium. The research will focus on improving the editing efficiency and specificity of Go-Genome through genome-editing experiments. Evogene is also conducting proof-of-concept experiments in plant tissue for its own product development activities. The approval of the second period is seen as a vote of confidence in the Israeli research community and could lead to new commercial directions for Evogene.
Investment
growth-positive
Evogene Announces Ms. Sarit Firon to become Evogene's Chairperson of the Board
Evogene Ltd. has announced the appointment of Ms. Sarit Firon as the new Chairperson of the Board, following the decision of Mr. Martin Gerstel not to stand for re-election after almost two decades in the role. Ms. Firon, an accomplished investor with over 27 years of experience, is expected to bring her expertise in building companies and leading them to IPOs and acquisitions to Evogene. The company, a computational biology firm focused on revolutionizing product development in the life sciences industry, has expressed confidence in Ms. Firons ability to lead the company and its subsidiaries to the next level of value creation. Evogene is known for its predictive discovery and development capabilities and has product pipelines in various sectors, including human health, agriculture, and medical cannabis.
Management Changes
growth-positive
Evogene Prices $12 Million Registered Direct Offering
Evogene Ltd. has entered into definitive agreements for a registered direct offering, which is expected to result in gross proceeds of $12 million. The company plans to use the net proceeds to further develop its product pipelines, enhance its computational predictive biology platform, and for general corporate purposes. The offering is expected to close on or before November 3, 2020.
Investment
growth-positive
Evogene (EVGN) Raises $10 Million In Equity Led Investment From ARK And Alpha Capital
Evogene Ltd. has raised $10 million in equity investment led by ARK Investment Management and Alpha Capital Anstalt. The funds will be used to develop product pipelines, enhance the computational predictive biology platform, and for general corporate purposes. Evogenes CPB platform utilizes Big Data and Artificial Intelligence to guide the development of life-science products. The company is advancing product pipelines in various industries through its subsidiaries. The registered direct offering is being made under Evogenes shelf registration statement.
Investment
growth-positive
Evogene teams with Weizmann Nobel laureate on microbiomes
Evogene Ltd.s biopharmaceutical unit Biomica has announced a collaboration with the Weizmann Institute of Science to develop a selective treatment against antibiotic resistant strains of Staphylococcus aureus infection. The collaboration aims to use Prof. Ada Yonaths discoveries in high-resolution crystal structure to design and develop new types of selective, narrow spectrum antibiotics agents. Biomica will utilize its computational technology to identify specific molecules that selectively target and inhibit the large ribosomal subunit of the pathogenic Staphylococcus aureus. The collaboration holds great potential in fighting global antibiotics resistance.
Partners
growth-positive
Evogene enters medical cannabis sector
Evogene, an Israeli agritech company, is setting up a subsidiary called Cannonic to engage in the medical cannabis sector. The company has developed computational systems for analyzing big data in order to mine insights about plant genetics and functioning, making it suitable for the cannabis field. Evogene plans to sell knowledge to cannabis companies and independently develop unique strains. The company aims to bring products to market relatively quickly due to the great need and the paucity of direct competition in its specific niche. Evogenes market cap was NIS 158 million at the start of trading on the TASE.
Expand
growth-positive
Genetic Crop Design Company Evogene Sets Up Agricultural Biology Subsidiary
Evogene Ltd. has announced the establishment of its new agricultural biology subsidiary, LaVie Bio Ltd. LaVie will focus on food quality and agricultural sustainability and productivity by introducing microbiome-based ag-biological products. Evogene uses computational predictive biology to develop novel crop strains and pesticides. The company launched its ag-biologicals division in 2015. Ido Dor, the former general manager of Evogenes ag-biologicals division, has been appointed as the CEO of LaVie. Ofer Haviv, Evogenes CEO, will serve as the chairman of the board of directors of the new subsidiary.
PartnersManagement Changes
growth-positive
Evogene and TMG Announce Collaboration to Develop Nematode Resistant Soybean through Genome Editing
Evogene Ltd. has announced a collaboration with TMG - Tropical Melhoramento & Genética S/A for the development of non-GMO nematode resistant soybean. Evogene will utilize its CPB platform to identify the required genome edits to attribute nematode resistance in soybean, while TMG will validate the efficacy of the edited soybeans in greenhouse assays and field trials in Brazil. The agreement provides commercialization rights for the resulting products by both parties, subject to royalty payments. Evogene will receive an undisclosed down-payment and a development milestone payment. Nematode parasites cause significant yield losses in soybean crops, and this collaboration aims to develop a solution to this problem. The collaboration is expected to bring excellent results to soybean growers worldwide.
Partners
growth-positive
Evogene teams with BASF on insecticides
Evogene Ltd. has signed an agreement with BASF to jointly develop a new family of insecticides. The two companies have achieved their first milestone in the cooperation by selecting targets within the insect for the new insecticide. Evogene will utilize its big data system to design molecules capable of reaching those targets. BASF will be responsible for field testing the materials discovered by Evogene. The cooperation marks an important step for Evogenes chemical division and strengthens their relationship with BASF. Evogene was originally a spinoff of Compugen and has applied its big data capabilities to the discovery of plant characteristics. The company is now expanding into the insecticide field.
Partners
growth-positive
Evogene and Marrone Bio Innovations Announce Phase Advancement in their Insect Control Collaboration
Evogene Ltd. and Marrone Bio Innovations Inc. have announced the advancement of genes into Phase I in their insect control collaboration. The genes, isolated from MBIs microbial assets, showed insecticidal activity against insects in model plants. The selected genes will now be advanced to soybean validation in greenhouse and field trials. The collaboration aims to bring novel microbe-based insect control solutions to market. Evogenes Computational Predictive Biology (CPB) platform was used to analyze the genetic potential of MBIs insecticidal microbial collection. The companies have agreed to share revenues from any resulting products. The soybean seed market is estimated at $8 billion, and the soybean insecticide market is estimated at $2.5 billion annually.
PartnersInvestment
growth-positive
Evogene unit Biomica designs molecules to analyze bacteria
Biomica, a spin-off of Evogene, is using big data to analyze the interface between the bacterial environment of human beings and the human body. The company is developing a molecule capable of destroying specific bacteria, with a focus on cancer treatment, digestive tract diseases, and infectious diseases. Biomica will also examine the effect of existing probiotic products on human health. Evogene holds a 90% stake in Biomica and plans to be involved in the company in the long term. The article was published on April 30, 2018.
Partners
growth-positive
Evogene and DuPont team to improve corn yields
Evogene Ltd. has signed a major multiyear collaboration deal with DuPont Pioneer to develop microbiome-based seed treatments in corn. The collaboration aims to provide farmers with innovative bio-stimulant seed treatment products that protect and maximize corn yield. Under the agreement, DuPont will provide access to its seed treatment application technology and product development expertise, while Evogene will apply its predictive computational biology platform and microbial formulation and fermentation technologies. The collaboration is expected to drive research and development of ag-biological solutions and improve agricultural productivity. The bio-stimulant market is estimated to be worth over $1.6 billion with a projected annual growth rate of 10%. Specific financial terms were not disclosed.
Partners
growth-positive
Genetic Crop Design Company Evogene Amends Bayer Collaboration Agreement
Evogene Ltd. has announced an amendment of its corn disease resistance research agreement with the crop science division of Bayer AG. The agreement will now focus on genome editing targets for evaluation, and any promising targets will be continued by Bayer. The collaboration aims to develop corn seeds resistant to fungal diseases, which cause $7 billion in annual damages in the U.S. alone.
Partners
growth-positive
Evogene reports progress in corn agreement with Monsanto
Evogene has announced success in its plant model trial for strains that improve the resistance of corn to fusarium disease. The trial is part of Evogenes framework agreement with Monsanto, with milestone payments and royalties involved. Evogene did not disclose the specific payment for the current milestone but plans to continue with further trials. The merger between Monsanto and Bayer is expected to create a giant agricultural conglomerate, to which the agreements between Monsanto and Evogene will be transferred.
PartnersInvestment
N/A
BRIEF-Evogene and Marrone Bio Innovations disclose positive results in insect control
The article does not provide any specific information about Reuters or any related events.
growth-positive
http://www.bloomberg.com/news/articles/2016-01-05/insect-beating-seeds-are-growth-engine-for-evogene-ceo-says
Evogene Ltd., an Israeli plant genomics company, expects the next generation of insect-resistant seeds to be one of its main growth engines. The company experienced a 20 percent stock rally in December 2015, outperforming its global peers. Evogene is now focusing on the genomics of bacteria, which is a new field of activity for the company. The president and CEO, Ofer Haviv, believes that this new area will drive growth for the company in the coming years.
CustomersPartners
growth-positive
Evogene teams with BASF on herbicide development
Evogene has entered into a cooperation agreement with BASF to discover and develop novel herbicides. Evogene will use its technology to identify new chemicals potentially useful as herbicides, and BASF will use Evogenes plant platform to screen the candidate chemicals. The agreement has the potential to expand into fungicides and pesticides. Evogene has agreements with companies such as Monsanto, Syngenta, and Bayer, but this is its first agreement in the chemical field. The cooperation aims to address the issue of weed resistance and develop herbicides with novel modes of action.
Partners
growth-positive
Evogene Develops GMO Tech To Secure The Food Of The Future
Israels Evogene is using GMO technology to improve crop quality and productivity. The companys PointHit platform analyzes molecules in weeds to identify key plant macro-molecules responsible for essential biological processes. This allows for the development of more effective herbicides. Monsanto, a major investor in Evogene, has shown interest in the technology. Critics argue that genetically modified crops have damaging effects, while others claim the studies are inconclusive.
PartnersInvestment
growth-positive
Evogene opens new crop protection R&D center
Evogene Ltd. has opened dedicated R&D facilities at its Rehovot facility to support the companys product programs focusing on fungus, insect, and weed control. The company sees crop protection as a major focus of growth and expansion and looks to develop novel seed traits as well as seed external solutions for these areas. Evogene has significantly increased its activities in the area of crop protection over the past year and has invested $10 million in expanding its existing knowledge base, computational platforms, and testing and validation capabilities. The newly completed facilities support these new and increased areas of activity.
Expand
growth-positive
Evogene raises $74m in New York
Evogene completed its offering on the NYSE, raising $74 million at $14.75 per share. The offering reflects a company value of $355 million. Monsanto invested $12 million in the offering and now owns 9.87% of Evogene. The investment is part of the expanded collaboration between the two companies. Evogene plans to use the funds to speed up time to market for its products, invest in independent product development, and invest in additional technology infrastructures.
Investment
growth-positive
Agrotech co EvoGene to raise $10m on TASE
EvoGene Ltd., a spin-off of Compugen Ltd., plans to hold an IPO on the Tel Aviv Stock Exchange. The company has raised $11 million to date and aims to raise $10 million at a valuation of $30-35 million. EvoGene uses bioinformatics technology to develop genetically enhanced plants. It has several projects focused on changing plants characteristics, such as developing crops that require less fertilizer, drought-resistant and saline-resistant crops, and plants that produce a human protein for the pharmaceutical industry. Protalix Biotherapeutics Inc. is a partner in one of EvoGenes projects. The IPO is expected to be underwritten by Clal Finance Underwriting Ltd.
InvestmentPublic Trading
Evogene Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 110 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 18 classification IDs that could be used for matching.
Evogene Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | video or image, markets |
| BI Verification | Yamila Silbert |
| Registrar ID | 512838723 |
| Crunchbase | evogene |
| Phone | +97289311900 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-10-03T00:00:00.000Z |
| Created | 2014-05-01T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on TASE on Jun, 2007;Public on NASDAQ on Nov, 2013; |